Chemours (CC) Q3 Earnings Miss Estimates

Chemours (CC) reported Q3 2025 adjusted earnings of $0.20 per share, missing the Zacks Consensus Estimate of $0.24 by 16.67% and representing a 50% year-over-year decline, though revenue of $1.5 billion slightly exceeded expectations. The company's shares have significantly underperformed the S&P 500 year-to-date, and with unfavorable estimate revisions and its industry ranking in the bottom 9%, the stock currently holds a Zacks Rank #5 (Strong Sell), indicating a negative near-term outlook.

Analysis

Chemours (CC) reported Q3 2025 adjusted earnings per share of $0.20, significantly missing the Zacks Consensus Estimate of $0.24 by 16.67% and marking a 50% year-over-year decline from $0.40. Despite this, quarterly revenues of $1.5 billion slightly exceeded consensus by 0.19%, though remaining flat compared to the prior year. This quarter's EPS miss follows a beat in the previous quarter, with the company having surpassed EPS estimates two times in the last four quarters.

The earnings miss exacerbates Chemours' significant year-to-date underperformance, with its shares down 28.7% compared to the S&P 500's 15.6% gain. Unfavorable estimate revisions prior to this release have resulted in a Zacks Rank #5 (Strong Sell), indicating an expectation of near-term market underperformance.

Adding to the bearish sentiment, the Chemical - Diversified industry, where Chemours operates, is positioned in the bottom 9% of Zacks industries. Historical data suggests industries in the bottom half significantly underperform, posing a structural headwind for CC. Future stock movement will largely depend on management's commentary during the upcoming earnings call, which could influence the current consensus EPS estimate of $0.21 for the coming quarter.

The company's ability to sustain its revenue performance, having topped consensus revenue estimates three times over the last four quarters, offers a minor counterpoint, but is overshadowed by the earnings decline and negative outlook.

Key Decisions for Investors

• Investors should exercise extreme caution given the significant earnings miss, negative analyst outlook, and challenging industry environment.
• Consider reviewing existing positions in CC due to the strong sell rating and substantial year-to-date underperformance.
• Await management's detailed commentary on the earnings call for any potential strategic shifts or forward guidance before making new investment decisions.